C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 1 filers reported holding C4 THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $461,749 | -27.3% | 248,252 | +7.5% | 0.00% | – |
| Q2 2023 | $635,344 | -36.2% | 231,034 | -27.1% | 0.00% | – |
| Q1 2023 | $995,408 | -52.7% | 317,009 | -11.1% | 0.00% | -100.0% |
| Q4 2022 | $2,104,247 | -31.9% | 356,652 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $3,089,000 | +50.0% | 352,125 | +28.9% | 0.00% | 0.0% |
| Q2 2022 | $2,060,000 | -68.9% | 273,189 | +0.0% | 0.00% | -50.0% |
| Q1 2022 | $6,627,000 | -22.2% | 273,137 | +3.2% | 0.00% | -33.3% |
| Q4 2021 | $8,522,000 | -26.8% | 264,651 | +1.6% | 0.00% | -25.0% |
| Q3 2021 | $11,637,000 | +118.7% | 260,452 | +85.3% | 0.00% | +100.0% |
| Q2 2021 | $5,321,000 | +106.3% | 140,594 | +101.7% | 0.00% | +100.0% |
| Q1 2021 | $2,579,000 | +16.6% | 69,712 | +4.4% | 0.00% | 0.0% |
| Q4 2020 | $2,212,000 | – | 66,742 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |